Two joint ventures in China for Finnish AQ Biotech, built through a Hong Kong hub
“Hong Kong functions as a super-connector, blending Western corporate governance with seamless access to mainland China.” That’s how Timo Teimonen, CEO of Finnish AQ Biotech, describes the structure behind a major milestone: two joint venture agreements in mainland China, each anchored by a world-class clinical hospital. For a Nordic biotech startup, it’s a leap onto a vast stage.
AQ Biotech, based in Turku in Finland, has built a non-invasive, antibody-free diagnostics platform that uses phage-biosensors to detect serious diseases at an early stage, with a focus on cancers, infectious diseases and neurodegenerative disorders. The goal is an early and accurate screening and diagnosis that is more comfortable for the patients they are facing today and thus easier to say yes, but also more affordable than invasive tests for the hospitals. Now that technology is heading into one of the largest healthcare markets in the world, through two joint ventures secured in mainland China within a week of each other.
“Both regions give us access to world-class clinical research hospitals serving patient populations in the tens, even hundreds, of millions,” says Timo Teimonen, CEO of AQ Biotech.
In Nanjing, AQ Biotech has partnered with OG Pharmaceuticals and integrated clinically with Jiangsu Cancer Hospital to deploy its oncology platform for early-stage prostate and urinary tract cancers. In Chengdu, a partnership with Sichuan Yiaijinxuan Technology, working alongside West China Hospital at Sichuan University, focuses on non-invasive screening for the early detection of Parkinson’s disease. Landing two such agreements at once came down to structure. Years of careful research validation with local partners built scientific credibility, competitive funding such as the MOST and Business Finland joint call added external validation, and the whole arrangement was anchored safely through Hong Kong, with AQ Biotech keeping full ownership of its core global IP while the local ventures are focused on upscaling via massive patient populations in China. This upscaling enables AQ Biotech´s fast entry to global diagnostics markets.
“Hong Kong has become the vital unlock for us. It gives us the legal framework and corporate foundation to manage and protect our operations in both Chengdu and Nanjing from a single, trusted international hub,” says Timo.
That Hong Kong base is where Leap4Growth came in. The programme’s hands-on support helped the team integrate into Hong Kong’s business and startup ecosystem and gave them the confidence to set up their global operations hub there, AQ Biotech Global Ltd. What surprised them most was the pace. “We were genuinely impressed by how fast Hong Kong’s startup ecosystem and administrative processes can react and offer the support you need to establish operations there,” says Timo. With both ventures signed and its cross-border structure in place, AQ Biotech is now preparing to launch a Series A funding round in the second half of the year to accelerate its global growth.
Want to know more about AQ Biotech?
LinkedIn: www.linkedin.com/company/aqbiotech
